Canada Life
BLCM

Canada Life’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Canada Life’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,238
Closed -$35K – 2712
2018
Q4 		$35K Buy
+1,238
New +$54.9K ﹤0.01% 2471

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Canada Life's BLCM Position: Q1 2019 in Review

Canada Life sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2019, closing a stake of 1,238 shares — an estimated $35K sold.

Canada Life first reported a position in BLCM in Q4 2018 and held it in 1 quarter. The position peaked at $35K in Q4 2018. 94 funds tracked by Wall St. Rank hold BLCM as of Q1 2019.

  • Canada Life reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Canada Life sold 1,238 Bellicum Pharmaceuticals, Inc. shares in Q1 2019, an estimated $35K.
  • Canada Life first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Canada Life's Bellicum Pharmaceuticals, Inc. position peaked at $35K in Q4 2018.
  • 94 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2019.

Based on Canada Life's 13F filing for Q1 2019, filed 8 May 2019.